MHRA backs gene therapy in battle with ‘bubble baby’ disease – The Pharma Letter (registration)
|
MHRA backs gene therapy in battle with 'bubble baby' disease
The Pharma Letter (registration) The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Promising Innovative Medicine Designation to OTL-101 for the treatment of adenosine deaminase severe combined immunodeficiency, commonly known as ADA-SCID, … |
